Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at email@example.com.
Geriatric Consultation Did Not Significantly Improve Survival in Hematologic Malignancies But Increased End of Life Care DiscussionsMay 17th 2022
Geriatric consultations vs standard of care for patients with hematologic malignancies who were pre-frail or frail did not significantly improve survival at 1 year but did increase discussions on end-of-life goals of care.
Brexucabtagene Autoleucel May Be a Cost-Effective Treatment for Relapsed/Refractory MCLMay 17th 2022
Treatment with brexucabtagene autoleucel appears to be a cost-effective treatment for patients with relapsed/refractory mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor.
IMNI Does Not Significantly Improve DFS in Node+ Breast Cancer But Could Benefit Medically/Centrally Located TumorsMay 12th 2022
Patients with node-positive breast cancer did not have a significant improvement in disease-free survival with the addition of internal mammary node irradiation to regional nodal irradiation; however, patients with medically or centrally located tumors could benefit.
Early Intrathecal Therapy Appears Feasible, Efficacious for ICANS in R/R B-cell Non-Hodgkin LymphomaMay 12th 2022
Patients with relapsed/refractory B-cell non-Hodgkin lymphoma who experienced grade 3 or higher immune effector cell–associated neurotoxicity syndrome who were treated with early intrathecal therapy experienced improved survival.
SBRT Plus Pembrolizumab and Trametinib May Become a Promising Treatment Option in Locally Recurrent Pancreatic CancerMay 11th 2022
Stereotactic body radiotherapy plus pembrolizumab and trametinib could potentially become a novel treatment strategy for patients with locally recurrent pancreatic cancer following surgery.
SKYSCRAPER-1 Trial Does Not Meet End Point of PFS With Tiragolumab Plus Atezolizumab in NSCLCMay 11th 2022
The primary end point of progression-free survival was not met in the phase 3 SKYSCRAPER-1 trial assessing tiragolumab plus atezolizumab for patients with PD-L1–high locally advanced or metastatic non–small cell lung cancer.
Dearth of Participation From Black Patients Noted in CAR T Clinical Trials Supporting FDA ApprovalsMay 9th 2022
Investigators identified that in pivotal clinical trials supporting FDA approvals of CAR T-cell therapies for patients with hematologic cancer, Black patients were significantly underrepresented.
Hospital-Based Ovarian Cancer Traceback Program Yields Minimal Increase in Genetic Counseling and TestingMay 7th 2022
Minimal increases in genetic testing and counseling were observed when using a traceback program to contact patients with ovarian cancer and surrogates via phone, and was not time sensitive.
Polatuzumab Vedotin Is Safe, Efficacious, But Yields Short Duration of Response in R/R LBCLMay 6th 2022
Although treatment with polatuzumab vedotin (Polivy) after anti-CD19 CAR T-cell therapy was safe and effective for patients with relapsed/refractory large B-cell lymphoma, it had a short duration of response.
MRD Status at Serial ASCT Time Point Are Positive Predictors for Survival Outcomes in Multiple MyelomaMay 6th 2022
Minimal residual disease status 3 months and 6 months following autologous stem-cell transplant could be predictive of progression-free survival and overall survival outcomes in multiple myeloma.
European Commission Approves Pembrolizumab Plus Chemotherapy With or Without Bevacizumab for Cervical CancerMay 3rd 2022
Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.